-transparent.png){kind=logo}
The anti-platelet-activating factor effect of YM264 was examined in a variety of in vitro and in vivo test systems. YM264 inhibited [3H] platelet-activating factor binding to rabbit platelet membranes with a pKi value of 8.85. YM264 inhibited the platelet-activating factor-induced human, rabbit and guinea-pig platelet aggregation with pA2 values of 8.68, 8.33 and 8.14, respectively. However, at 10(-4) M the compound did not affect rabbit and human platelet aggregation induced by ADP, collagen arachidonic acid and epinephrine. YM264 reversed a platelet-activating factor-induced hypotension is anesthetized rats with an ED50 value of 0.005 mg/kg, i.v. Administered orally, YM264 inhibited platelet-activating factor-induced death in mice, hemoconcentration in rats and increase in vascular permeability in guinea-pigs with ED50 values of 0.19, 0.30 and 0.49 mg/kg, p.o., respectively. YM264, at 1 and 3 mg/kg, p.o., showed a significant anti-platelet-activating factor effect in a rat hemoconcentration model up to 6 hr after treatment. Moreover, in ex vivo experiments in guinea-pigs, YM264, at the doses of 0.3 to 3 mg/kg, p.o., shifted the dose-response curves of platelet-activating factor-induced platelet aggregation to the right in a parallel manner. These results indicate that YM264 is a selective, potent and orally active platelet-activating factor antagonist.
T Yamada, and
K Tomioka, and
M Saito, and
M Horie, and
T Mase, and
H Hara, and
H Nagaoka
March 1990,
The Journal of pharmacology and experimental therapeutics,
T Yamada, and
K Tomioka, and
M Saito, and
M Horie, and
T Mase, and
H Hara, and
H Nagaoka
June 1993,
Journal of lipid mediators,
T Yamada, and
K Tomioka, and
M Saito, and
M Horie, and
T Mase, and
H Hara, and
H Nagaoka
January 1997,
The Journal of pharmacology and experimental therapeutics,
T Yamada, and
K Tomioka, and
M Saito, and
M Horie, and
T Mase, and
H Hara, and
H Nagaoka
September 1990,
Molecular pharmacology,
T Yamada, and
K Tomioka, and
M Saito, and
M Horie, and
T Mase, and
H Hara, and
H Nagaoka
January 1987,
Advances in experimental medicine and biology,
T Yamada, and
K Tomioka, and
M Saito, and
M Horie, and
T Mase, and
H Hara, and
H Nagaoka
December 1990,
Prostaglandins,
T Yamada, and
K Tomioka, and
M Saito, and
M Horie, and
T Mase, and
H Hara, and
H Nagaoka
January 1995,
Advances in prostaglandin, thromboxane, and leukotriene research,
T Yamada, and
K Tomioka, and
M Saito, and
M Horie, and
T Mase, and
H Hara, and
H Nagaoka
April 2010,
The Journal of pharmacology and experimental therapeutics,
T Yamada, and
K Tomioka, and
M Saito, and
M Horie, and
T Mase, and
H Hara, and
H Nagaoka
November 1988,
The Journal of pharmacology and experimental therapeutics,
T Yamada, and
K Tomioka, and
M Saito, and
M Horie, and
T Mase, and
H Hara, and
H Nagaoka
June 1999,
The Journal of pharmacology and experimental therapeutics,
